Testing effectiveness (Phase 2)Study completedNCT00136539What this trial is testingNeoadjuvant Therapy With Herceptin and Taxol for Breast CancerWho this might be right forBreast Cancer Harold J. Burstein, MD, PhD 41
Large-scale testing (Phase 3)Looking for participantsNCT07043725What this trial is testingA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerWho this might be right forHER2-positive Breast Cancer Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 544
Testing effectiveness (Phase 2)UnknownNCT01709370What this trial is testingLetrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal WomenWho this might be right forER Positive, HER2 Negative Breast Cancer Organisation for Oncology and Translational Research 45
Large-scale testing (Phase 3)Active Not RecruitingNCT04873362What this trial is testingA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyWho this might be right forBreast Cancer Hoffmann-La Roche 1,188
Testing effectiveness (Phase 2)Ended earlyNCT01498588What this trial is testingTrial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast CancerWho this might be right forBreast NeoplasmsBreast CancerBreast Tumors+3 more Emory University 7
Post-approval studies (Phase 4)Looking for participantsNCT05525767What this trial is testingChemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast CancerWho this might be right forSolid Tumor Hebei Medical University Fourth Hospital 75
Not applicableLooking for participantsNCT07546695What this trial is testingRole of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC StudyWho this might be right forBreast Cancer University Hospital, Basel, Switzerland 600
Testing effectiveness (Phase 2)Looking for participantsNCT04329065What this trial is testingConcurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast CancerWho this might be right forAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8 University of Washington 25
Testing effectiveness (Phase 2)Study completedNCT01855828What this trial is testingPhase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast CancerWho this might be right forHer2-Positive Breast Cancer Yale University 50
Testing effectiveness (Phase 2)Looking for participantsNCT07220135What this trial is testingTrial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast CancerWho this might be right forBreast Cancer University of Kansas Medical Center 100
Testing effectiveness (Phase 2)Looking for participantsNCT06927180What this trial is testingSHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCWho this might be right forBreast Cancer Early Stage Breast Cancer (Stage 1-3) Henan Cancer Hospital 180
Testing effectiveness (Phase 2)Active Not RecruitingNCT06068985What this trial is testingClassifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-BlockadeWho this might be right forBreast CancerHER2-positive Breast Cancer Latin American Cooperative Oncology Group 63
Testing effectiveness (Phase 2)Looking for participantsNCT07407920What this trial is testingPh2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialWho this might be right forAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage HER2-Positive Breast Carcinoma+1 more M.D. Anderson Cancer Center 120
Large-scale testing (Phase 3)UnknownNCT05871918What this trial is testingA Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast CancerWho this might be right forHER-2 Positive Breast Cancer Tianjin Medical University Cancer Institute and Hospital 832
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07109284What this trial is testingSKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast CancerWho this might be right forER+HER2- Breast Cancer West China Hospital 55
Testing effectiveness (Phase 2)UnknownNCT04197687What this trial is testingTPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryWho this might be right forBreast AdenocarcinomaStage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7+5 more Academic and Community Cancer Research United 480
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07307287What this trial is testingSHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II StudyWho this might be right forSHR-A1811HER2-Postive Breast CancerHR+ Breast Cancer+2 more Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)UnknownNCT00777673What this trial is testingPreoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.Who this might be right forBreast Cancer University of Tennessee Cancer Institute 60
Testing effectiveness (Phase 2)UnknownNCT05749575What this trial is testingChidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.Who this might be right forBreast Cancer Sun Yat-sen University 28
Testing effectiveness (Phase 2)Looking for participantsNCT07383818What this trial is testingNeoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)Who this might be right forHR Positive/HER2 Low Breast Cancer First Affiliated Hospital of Zhejiang University 111